Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study
Authors' conclusion
Omnipod DASH was associated with improvements in HbA1c in PwT1D "new-to-pump" and maintained previous HbA1c levels in those "established-on-pump". User satisfaction in all groups and TDD reduction in those "new-to-pump" were reported.
Study context
- Population
- People with T1D initiated on Omnipod DASH, 11 centres (NHS); 66.7 % female, 92 % White British, median age 41 years (IQR 20–50), diabetes duration 20 years (IQR 11–31)
- Participants
- 276 people11 centers
- Exposure
- Follow-up vs baseline after initiation of Omnipod DASH
- Outcome
- HbA1c change from baseline
- Follow-up
- 3 years (IQR 1.5-3.2)
Methodological detailsmulticentre, before–after (baseline vs follow-up)
- Multicentre
- Before–after (baseline vs follow-up)
Main finding
As reported in the abstract
Baseline Hemoglobin A1c (HbA1c)
8.0 ± 1.3 %
64 ± 14 mmol/mol
HbA1c reduction, total population
0.3 %
3 mmol/molp = 0.002
HbA1c reduction, new-to-pump
0.4 %
5 mmol/molp = 0.001
Observational data: associations, not effects.
Further findings
TDD in new-to-pump · baseline vs follow-up
- TDD decreased, baseline vs follow-up
- 44.9 ± 21.0units vs 38.1 ± 15.4units, p = 0.002
Positive impact on quality of life
- Of those asked, stated positive impact on QoL
- 141/143 (98.6 %)
Original publication
Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study. Diabetes Res Clin Pract. Published 27 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →